Physician profile
Joseph Ye
NPI 1700881422
$114,841.07
in general payments reported to CMS, 2019-2025
100 companies · $14K in 2025
The $14K reported for 2025 was more than what 84% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $8,922 · 2021: $8,789 · 2022: $27K · 2023: $20K · 2024: $14K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,529 · Travel and Lodging: $1,368 · Education: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,255.00 |
| Food and Beverage | $14,111.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,528.85 |
| Travel and Lodging | $1,368.21 |
| Education | $885.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $19,357.18 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Genentech USA, INC. | $7,190.04 | 2019-2025 | Lunsumio, Venclexta, Polivy |
| Abbvie INC. | $6,562.24 | 2019-2025 | Venclexta |
| Karyopharm Therapeutics INC. | $6,514.03 | 2020-2024 | Xpovio |
| Rigel Pharmaceuticals, INC. | $5,862.56 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Astellas Pharma Global Development | $5,662.00 | 2020-2024 | Vyloy |
| Genentech, INC. | $5,578.18 | 2023 | Venclexta |
| Kite Pharma, INC. | $4,280.12 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $3,405.70 | 2019-2024 | Onivyde |
| Jazz Pharmaceuticals INC. | $3,350.47 | 2019-2025 | Zepzelca |
| Novartis Pharmaceuticals Corporation | $3,311.31 | 2019-2025 | |
| Celgene Corporation | $3,188.56 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $2,862.07 | 2019-2025 | Enhertu, Datroway |
| Sobi, INC | $2,742.95 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,256.60 | 2019-2025 | Opdivo, Opdualag, Augtyro |
Show all 100 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,223.54 | 2019-2025 | |
| Incyte Corporation | $2,148.33 | 2020-2025 | Zynyz, Jakafi, Monjuvi |
| Genmab U.S., INC. | $2,111.35 | 2023-2025 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,025.51 | 2019-2025 | Gilotrif |
| Astellas Pharma US INC | $1,975.74 | 2019-2025 | Vyloy, Xospata, Padcev |
| Exelixis INC. | $1,653.36 | 2019-2025 | Cabometyx |
| Genzyme Corporation | $1,634.93 | 2019-2025 | |
| Morphosys, US INC. | $1,553.65 | 2021-2023 | Monjuvi |
| G1 Therapeutics, INC. | $1,521.47 | 2022 | |
| Seagen INC. | $1,286.06 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Amgen INC. | $1,201.24 | 2019-2023 | Kyprolis, Blincyto |
| Merck Sharp & Dohme LLC | $1,128.84 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Scientific Affairs, LLC | $1,080.00 | 2025 | Rybrevant |
| Pharmacyclics LLC, An Abbvie Company | $945.97 | 2019-2023 | Imbruvica, Epkinly |
| Janssen Biotech, INC. | $676.20 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| Lilly USA, LLC | $671.92 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $564.29 | 2019-2025 | Libtayo, Lynozyfic |
| Bayer Healthcare Pharmaceuticals INC. | $545.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $459.63 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Dendreon Pharmaceuticals LLC | $373.27 | 2019-2025 | Provenge |
| Tersera Therapeutics LLC | $370.76 | 2020-2025 | Zoladex, Quzyttir, Xermelo |
| Eisai INC. | $367.56 | 2019-2025 | |
| Taiho Oncology, INC. | $363.75 | 2020-2025 | |
| Stemline Therapeutics INC. | $340.10 | 2021-2025 | Orserdu |
| Beigene USA, INC. | $298.04 | 2020-2025 | Brukinsa, Tevimbra |
| Aveo Pharmaceuticals, INC. | $268.31 | 2021-2025 | Fotivda |
| Array Biopharma INC | $221.12 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Deciphera Pharmaceuticals INC. | $217.80 | 2020-2025 | Qinlock, Romvimza |
| Coherus Oncology, INC. | $197.16 | 2020-2024 | |
| Clovis Oncology, INC. | $195.37 | 2019-2021 | |
| Caris Mpi, INC. | $183.68 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $167.25 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.34 | 2019-2025 | Fruzaqla |
| Puma Biotechnology, INC. | $155.00 | 2020-2025 | |
| Foundation Medicine, INC. | $153.05 | 2019-2023 | |
| Emd Serono, INC. | $144.66 | 2019-2025 | |
| Aurobindo Pharma USA, INC. | $137.33 | 2019 | |
| Tempus Ai, INC | $120.99 | 2024-2025 | Xt Cdx |
| Alnylam Pharmaceuticals INC. | $120.62 | 2025 | Givlaari |
| Beone Medicines USA, INC. | $116.01 | 2025 | Tevimbra, Brukinsa |
| Gilead Sciences, INC. | $115.93 | 2021-2025 | Trodelvy |
| Myovant Sciences INC. | $112.92 | 2021 | |
| Blueprint Medicines Corporation | $111.02 | 2020-2025 | Ayvakit |
| Mirati Therapeutics, INC. | $104.85 | 2023-2024 | Krazati |
| Agios Pharmaceuticals, INC. | $104.12 | 2019-2024 | Pyrukynd |
| Spectrum Pharmaceuticals INC. | $101.74 | 2019-2023 | Rolvedon |
| Apellis Pharmaceuticals, INC. | $101.30 | 2023-2024 | Empaveli |
| Janssen Pharmaceuticals, INC | $94.52 | 2021-2024 | Rybrevant, Xarelto |
| Dova Pharmaceuticals | $90.90 | 2019-2021 | |
| Tg Therapeutics, INC. | $81.72 | 2021-2022 | |
| Ge Healthcare | $80.52 | 2021-2022 | |
| Epizyme, INC. | $73.85 | 2020-2022 | |
| Tesaro, INC. | $66.93 | 2019 | |
| Syndax Pharmaceuticals, INC. | $65.38 | 2025 | |
| Pharmacosmos Therapeutics INC. | $64.38 | 2023-2025 | Monoferric |
| Alexion Pharmaceuticals, INC. | $63.55 | 2019-2020 | |
| Novocure INC. | $61.81 | 2019-2025 | Optune Gio |
| Immunocore Limited | $60.67 | 2025 | Kimmtrak |
| Heron Therapeutics, INC. | $56.70 | 2021 | |
| Sun Pharmaceutical Industries INC. | $55.17 | 2020-2023 | Yonsa, Odomzo |
| Sumitomo Pharma America, INC. | $53.42 | 2023-2025 | Orgovyx |
| Progenics Pharmaceuticals, INC. | $53.38 | 2025 | |
| Eusa Pharma (US) LLC | $52.96 | 2020-2022 | |
| Cti Biopharma Corp. | $46.31 | 2022-2023 | Vonjo |
| Myriad Genetic Laboratories, INC. | $45.35 | 2022-2025 | Myrisk |
| Sanofi-Aventis U.S. LLC | $45.19 | 2020-2023 | |
| Helsinn Therapeutics (U.S.), INC. | $43.87 | 2019-2021 | |
| Acrotech Biopharma INC. | $41.46 | 2023-2025 | Beleodaq |
| Accord Healthcare, INC. | $39.55 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $37.96 | 2023-2024 | |
| Sirtex Medical INC | $37.39 | 2020 | |
| Horizon Therapeutics Plc | $37.16 | 2019-2020 | |
| Octapharma USA, INC. | $36.75 | 2025 | Octagam Immune Globulin (Human) |
| Mylan Institutional INC. | $36.52 | 2019 | |
| Adaptive Biotechnologies Corporation | $35.21 | 2023-2025 | Clonoseq |
| United Therapeutics Corporation | $32.38 | 2019 | |
| Geron Corporation | $32.12 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $26.41 | 2025 | Panhematin |
| Iovance Biotherapeutics, INC. | $25.58 | 2025 | Amtagvi |
| Roche Diagnostics Corporation | $23.84 | 2020 | |
| Fennec Pharmaceuticals, INC. | $23.40 | 2025 | Fyarro |
| Kyowa Kirin, INC. | $19.56 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $19.34 | 2020 | |
| Legend Biotech USA INC. | $18.69 | 2025 | Carvykti |
| Innate Pharma, INC | $16.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,641.31 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.